DK3509591T3 - Nye jak1-selektive inhibitorer og anvendelser deraf - Google Patents
Nye jak1-selektive inhibitorer og anvendelser deraf Download PDFInfo
- Publication number
- DK3509591T3 DK3509591T3 DK17858944.6T DK17858944T DK3509591T3 DK 3509591 T3 DK3509591 T3 DK 3509591T3 DK 17858944 T DK17858944 T DK 17858944T DK 3509591 T3 DK3509591 T3 DK 3509591T3
- Authority
- DK
- Denmark
- Prior art keywords
- new
- selective inhibitors
- jak1 selective
- jak1
- inhibitors
- Prior art date
Links
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662403660P | 2016-10-03 | 2016-10-03 | |
| PCT/US2017/054668 WO2018067422A1 (en) | 2016-10-03 | 2017-09-30 | Novel jak1 selective inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3509591T3 true DK3509591T3 (da) | 2021-12-20 |
Family
ID=61831161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17858944.6T DK3509591T3 (da) | 2016-10-03 | 2017-09-30 | Nye jak1-selektive inhibitorer og anvendelser deraf |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | USRE50799E1 (enExample) |
| EP (1) | EP3509591B1 (enExample) |
| JP (1) | JP7089141B2 (enExample) |
| KR (1) | KR102399848B1 (enExample) |
| CN (2) | CN108366994B (enExample) |
| AU (3) | AU2017339417C1 (enExample) |
| DK (1) | DK3509591T3 (enExample) |
| EA (1) | EA201990523A1 (enExample) |
| ES (1) | ES2901216T3 (enExample) |
| HK (1) | HK1253040A1 (enExample) |
| HR (1) | HRP20211965T1 (enExample) |
| HU (1) | HUE058120T2 (enExample) |
| IL (3) | IL265358B (enExample) |
| MX (1) | MX390005B (enExample) |
| NZ (1) | NZ751284A (enExample) |
| PL (1) | PL3509591T3 (enExample) |
| PT (1) | PT3509591T (enExample) |
| RS (1) | RS62695B1 (enExample) |
| WO (1) | WO2018067422A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108366994B (zh) | 2016-10-03 | 2021-10-01 | 杭州高光制药有限公司 | 新型Jak1选择性抑制剂及其用途 |
| AU2018208516B2 (en) | 2017-01-11 | 2021-07-08 | Aqilion Ab | Novel amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof |
| IL282643B2 (en) | 2018-10-31 | 2025-08-01 | Incyte Corp | A selective jak1 inhibitor for use in a method of treating hematological disease |
| IL285999B2 (en) * | 2019-03-05 | 2026-01-01 | Incyte Corp | JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction |
| US11624751B2 (en) | 2019-03-19 | 2023-04-11 | Incyte Corporation | Biomarkers for vitiligo |
| KR102785014B1 (ko) * | 2019-06-06 | 2025-03-20 | 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. | 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태 |
| KR20250140639A (ko) * | 2019-06-06 | 2025-09-25 | 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. | 푸로이미다조피리딘 화합물의 합성 방법, 다형성 물질 및 염의 다형성 물질 |
| US20230192617A1 (en) | 2020-05-19 | 2023-06-22 | Bayer Cropscience Aktiengesellschaft | Azabicyclic(thio)amides as fungicidal compounds |
| WO2021249995A1 (en) | 2020-06-10 | 2021-12-16 | Bayer Aktiengesellschaft | Azabicyclyl-substituted heterocycles as fungicides |
| US20240307396A1 (en) * | 2021-06-07 | 2024-09-19 | The Regents Of The University Of California | Compositions and methods for treating celiac disease |
| JP2024543198A (ja) * | 2021-09-13 | 2024-11-19 | ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド | 中枢神経障害を治療する方法 |
| CN114213424B (zh) * | 2021-12-30 | 2023-05-26 | 杭州高光制药有限公司 | 一种呋喃[3，2-b]并吡啶衍生物的合成方法 |
| WO2025224600A1 (en) * | 2024-04-21 | 2025-10-30 | Biohaven Therapeutics Ltd. | Treatment of alpha-synucleinopathies and neuroprotection |
| WO2025248468A1 (en) | 2024-05-28 | 2025-12-04 | Biohaven Therapeutics Ltd. | Use of tyk2/jak1 inhibitors to treat amyloid-related imaging abnormalities (aria) |
| WO2026002028A1 (zh) * | 2024-06-26 | 2026-01-02 | 杭州多域生物技术有限公司 | 稠杂芳环类化合物、其药物组合物及其应用 |
| WO2026032213A1 (zh) * | 2024-08-08 | 2026-02-12 | 普罗思特(南京)生物科技有限公司 | 取代的三环衍生物及其应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3983092A (en) | 1975-01-20 | 1976-09-28 | Ciba-Geigy Corporation | Phenylindane diamine mixture and epoxy resin therewith |
| US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| DE3583799D1 (de) | 1985-01-11 | 1991-09-19 | Abbott Lab Ltd | Feste zubereitung mit langsamer freisetzung. |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| EP1101490B1 (en) | 1998-07-28 | 2005-04-13 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
| JP2000119271A (ja) * | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | １ｈ―イミダゾピリジン誘導体 |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US6800663B2 (en) | 2002-10-18 | 2004-10-05 | Alkermes Controlled Therapeutics Inc. Ii, | Crosslinked hydrogel copolymers |
| EP1720855A4 (en) | 2004-03-02 | 2008-12-17 | Smithkline Beecham Corp | HEMMER OF ACT ACTIVITY |
| CN101282974A (zh) * | 2005-08-04 | 2008-10-08 | 西特里斯药业公司 | 作为sirtuin调节剂的咪唑并吡啶衍生物 |
| CN101238186B (zh) | 2005-08-11 | 2012-10-24 | 3M创新有限公司 | 作为金属基底涂层的互穿聚合物网络及其制造方法 |
| WO2007039146A1 (en) | 2005-09-23 | 2007-04-12 | Smithkline Beecham Corporation | 4-carboxy pyrazole derivatives as anti-viral agents |
| US7879968B2 (en) | 2006-10-17 | 2011-02-01 | Taylor Made Golf Company, Inc. | Polymer compositions and golf balls with reduced yellowing |
| US20100280151A1 (en) | 2009-05-04 | 2010-11-04 | Toray Industries, Inc. | Toughened fiber reinforced polymer composite with core-shell particles |
| WO2011041399A2 (en) * | 2009-09-29 | 2011-04-07 | Tyrogenex, Inc. | Pi3k (delta) selective inhibitors |
| WO2011138657A1 (en) | 2010-05-04 | 2011-11-10 | Glenmark Pharmaceuticals S.A. | Aryl substituted olefinic compounds as pde10a inhibitors |
| WO2012022045A1 (en) * | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| BR112013008240A2 (pt) * | 2010-10-08 | 2017-12-12 | Abbvie Inc | compostos de furo [3-2-d] pirimidina |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| PH12013502670A1 (en) * | 2011-08-12 | 2016-07-29 | Nissan Chemical Ind Ltd | Tricyclic heterocyclic compounds and jak inhibitors |
| TW201319063A (zh) | 2011-10-04 | 2013-05-16 | Yakult Honsha Kk | 以四氫噻唑衍生物或其鹽為有效成分之醫藥品 |
| AU2013337824B2 (en) | 2012-11-01 | 2018-03-08 | Incyte Holdings Corporation | Tricyclic fused thiophene derivatives as JAK inhibitors |
| CN103450125B (zh) | 2013-07-18 | 2016-01-13 | 嘉兴中科化学有限公司 | 一种5-取代苯丙呋喃-2-羧酸及其衍生物的合成方法 |
| CA2926361A1 (en) | 2013-10-24 | 2015-04-30 | Abbvie Inc. | Jak1 selective inhibitor and uses thereof |
| JP2017514832A (ja) | 2014-04-30 | 2017-06-08 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ１抑制剤を調製する方法及びその新しい形態 |
| EP2940022B1 (en) | 2014-04-30 | 2020-09-02 | Masarykova Univerzita | Furopyridines as inhibitors of protein kinases |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| CN105418620B (zh) | 2014-09-23 | 2018-05-04 | 天津药明康德新药开发有限公司 | 一种4-(叔丁氧羰基)八氢呋喃并[3,2-b]吡啶-6-羧酸的合成方法 |
| WO2016100349A2 (en) | 2014-12-16 | 2016-06-23 | Rugen Holdings (Cayman) Limited | Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| CN106432232A (zh) | 2016-09-18 | 2017-02-22 | 苏州汉德创宏生化科技有限公司 | 1‑哌啶‑4‑基‑1,3‑二氢‑咪唑[4,5‑b]吡啶‑2‑酮的合成方法 |
| CN108366994B (zh) * | 2016-10-03 | 2021-10-01 | 杭州高光制药有限公司 | 新型Jak1选择性抑制剂及其用途 |
| AU2017377069B2 (en) | 2016-12-16 | 2020-07-23 | Janssen Pharmaceutica Nv | Small molecule inhibitors of the JAK family of kinases |
| CN107216334A (zh) | 2017-06-29 | 2017-09-29 | 上海吉尔多肽有限公司 | 一种6‑氯呋喃[3,2‑b]吡啶的合成方法 |
| KR20250140639A (ko) | 2019-06-06 | 2025-09-25 | 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. | 푸로이미다조피리딘 화합물의 합성 방법, 다형성 물질 및 염의 다형성 물질 |
| KR102803409B1 (ko) | 2019-06-06 | 2025-05-07 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | Atr 키나제 억제제로서의 2,4,6-삼치환된 피리미딘 화합물 |
| KR102785014B1 (ko) | 2019-06-06 | 2025-03-20 | 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. | 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태 |
| CN114213424B (zh) | 2021-12-30 | 2023-05-26 | 杭州高光制药有限公司 | 一种呋喃[3，2-b]并吡啶衍生物的合成方法 |
-
2017
- 2017-09-30 CN CN201780004442.5A patent/CN108366994B/zh active Active
- 2017-09-30 NZ NZ751284A patent/NZ751284A/en unknown
- 2017-09-30 MX MX2019003649A patent/MX390005B/es unknown
- 2017-09-30 US US18/122,295 patent/USRE50799E1/en active Active
- 2017-09-30 PL PL17858944T patent/PL3509591T3/pl unknown
- 2017-09-30 US US17/526,799 patent/USRE49834E1/en active Active
- 2017-09-30 EP EP17858944.6A patent/EP3509591B1/en active Active
- 2017-09-30 WO PCT/US2017/054668 patent/WO2018067422A1/en not_active Ceased
- 2017-09-30 EA EA201990523A patent/EA201990523A1/ru unknown
- 2017-09-30 CN CN202110514751.5A patent/CN113214278B/zh active Active
- 2017-09-30 HK HK18112420.5A patent/HK1253040A1/zh unknown
- 2017-09-30 DK DK17858944.6T patent/DK3509591T3/da active
- 2017-09-30 AU AU2017339417A patent/AU2017339417C1/en active Active
- 2017-09-30 KR KR1020197009016A patent/KR102399848B1/ko active Active
- 2017-09-30 US US16/333,994 patent/US10738060B2/en not_active Ceased
- 2017-09-30 HU HUE17858944A patent/HUE058120T2/hu unknown
- 2017-09-30 HR HRP20211965TT patent/HRP20211965T1/hr unknown
- 2017-09-30 RS RS20211521A patent/RS62695B1/sr unknown
- 2017-09-30 PT PT178589446T patent/PT3509591T/pt unknown
- 2017-09-30 JP JP2019517991A patent/JP7089141B2/ja active Active
- 2017-09-30 ES ES17858944T patent/ES2901216T3/es active Active
-
2019
- 2019-03-13 IL IL265358A patent/IL265358B/en unknown
-
2022
- 2022-02-17 AU AU2022201058A patent/AU2022201058B2/en active Active
- 2022-02-17 AU AU2022201061A patent/AU2022201061B2/en active Active
- 2022-03-10 IL IL291267A patent/IL291267B2/en unknown
- 2022-03-10 IL IL291265A patent/IL291265B2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3509591T3 (da) | Nye jak1-selektive inhibitorer og anvendelser deraf | |
| DK3658557T3 (da) | Tyk2-inhibitorer og anvendelser deraf | |
| EP3526222A4 (en) | TYK2 INHIBITORS AND THEIR USES | |
| EP3528816A4 (en) | TYK2 INHIBITORS AND USES THEREOF | |
| IL280863A (en) | Autotaxin inhibitors and uses thereof | |
| DK3389658T3 (da) | Glycosidasehæmmere og anvendelser deraf | |
| HUE061064T2 (hu) | Szelektív JAK1 gátlók | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| DK3436048T3 (da) | Neoantigener og fremgangsmåder til anvendelse deraf | |
| DK3365339T3 (da) | Nye ferroportin-hæmmere | |
| DK3160966T3 (da) | Mnk-inhibitorer og fremgangsmåder forbundet dermed | |
| DK3516160T3 (da) | Brøndanordning og tilhørende fremgangsmåder | |
| DK3302431T3 (da) | Taxanpartikler og anvendelse deraf | |
| DK3172213T3 (da) | Makrocykliske kinasehæmmere og anvendelser deraf | |
| EP4358558C0 (en) | APPARATUS AND METHOD FOR CAPACITY RATIO | |
| DK3193611T3 (da) | Mk2-inhibitorer og anvendelser deraf | |
| DK3555076T3 (da) | Nye phenylpropionsyrederivater og anvendelser deraf | |
| DK3356558T3 (da) | Sirs patogenbiomarkører og anvendelser deraf | |
| DK3474883T3 (da) | Komplementinhibitorer og anvendelser deraf | |
| DK3543240T3 (da) | URAT1-inhibitor og anvendelse deraf | |
| DK3621694T3 (da) | Lrrc33-inhibitorer og anvendelse heraf | |
| DK3447056T3 (da) | Multikinasehæmmerforbindelse, krystalform og anvendelse deraf | |
| DK3426243T3 (da) | 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf | |
| DK3532459T3 (da) | Lsd1-hæmmere og medicinske anvendelser deraf | |
| EP3595665A4 (en) | DUAL MAGL AND FAAH INHIBITORS |